Therapy of advanced-stage mature b-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): The results of a multicenter study

Journal of Pediatric Hematology/Oncology

Volumn 36, Issue 5, 2014, Pages 395-401

  Samochatova, Elena V ^a   Maschan, Alexey A ^a   Shelikhova, Larisa N ^a,b   Myakova, Natalia V ^a,b   Belogurova, Margarita B ^c   Khlebnikova, Olga P ^d   Shamardina, Anastasia V ^e   Ryskal, Olga V ^f   Roumiantseva, Julia V ^a   Konovalov, Dmitriy M ^a   Dubrovina, Maria E ^b   Rumyantsev, Alexander G ^a  

^a Clinical Center of Pediatric Hematology Oncology and Immunology   (Russian Federation)

^b Russian Pediatric Clinical Hospital   (Russian Federation)

^c Municipal Hospital No 31   (Russian Federation)

^d Regional Clinical Hospital   (Russian Federation)

^e Regional Clinical Hospital   (Russian Federation)

^f Territorial Pediatric Clinical Hospital   (Russian Federation)

Author keywords

children; combined immunochemotherapy; mature B cell non Hodgkin lymphoma; rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADVANCED CANCER; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BRONCHOSPASM; BURKITT LYMPHOMA; CANCER STAGING; CHILD; DRUG DOSE REDUCTION; DRUG FATALITY; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; INFECTION; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE OBSTRUCTION; OLIGURIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; TUMOR RECURRENCE; TUMOR RESISTANCE; URTICARIA;

ADOLESCENT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BURKITT LYMPHOMA; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDUCTION CHEMOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL RATE;

EID: 84903762765     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31829d4900     Document Type: Article

References (22)

1. Magrath I. The non-Hodgkin's lymphomas in children. In: Peckham M, Pinego H, Veronesi U, eds. Oxford Textbook of Oncology. Oxford: Oxford Medical Publications; 1995: 1809-1851.
2. Jaffe ES, Harris NL, Stein Y, et al. World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. Lion: JARC Press; 2001.
3. Patte C. Treatment strategies and outcome in childhood B-cell lymphoma. Pediatr Blood Cancer. 2006;46:834.
4. Woessmann W, Seidemann K, Mann G, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105:948-958.
5. Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM-90. Blood. 1999;94:3294-3306.
6. Gerrard M, Cairo MS, Weston C, et al. Results of the FAB LMB 96 international study in children and adolescents (C+A) with localised, resected B cell lymphoma (large cell [LCL], Burkitt's [BL] and Burkitt-like [BLL]). J Clin Oncol. 2003;22:795.
7. Samochatova EV, Aleinikova OV, Belikova LY, et al. Non- Hodgkin's lymphomas in children: clinical, diagnostic and therapeutic characteristics (data from clinics of Russia and Belarus). Gematol Transfuziol. 2001;6:1-10.
8. Wossmann W, Schrappe M, Meyer U, et al. Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. Ann Hematol. 2003;82:160-165.
9. Samochatova EV, Ostrovskaya AV, Karachunsky AI, et al. Value of verification of a type of non-Hodgkin lymphoma in children for therapeutical efficiency of the present-day protocols. Gematol Transfusiol. 2000;4:9-13.
10. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-116.
11. Coiffer B, Lepage E, Brier J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2000;346: 235-239.
12. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies. Curr Opin Immunol. 2008; 20:444-449.
13. Winiarska M, Glodkowska-Mrowka E, Bil J, et al. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci. 2011;16:277-306.
14. Murphy SB. Classification, staging and end results of treatment5 in childhood non-Hodgkin lymphoma: dissimilarities from lymphoma in adults. Semin Oncol. 1980;7: 332-339.
15. Patte C. Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin Haematol. 2002;15:695-711.
16. Haioun C, Itti E, Rahmouni A, et al. [18F]fluoro-2-deoxy- Dglucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106:1376-1381.
17. Samochatova EV, Myakova NV, Shelikhova LN, et al. Preliminary results of treatment of pediatric advance-staged mature B-cell NHL/B-ALL with intensive chemotherapy +rituximab: effectiveness and toxicity. Pediatr Blood Cancer. 2006;46:854-855.
18. Reiter A, Schrappe M, Parwaresch R, et al. Non-Hodgkin's lymphomas of childhood and adolescents: results of a treatment stratified for biologic subtypes and stage - a report of the BFM group. J Clin Oncol. 1995;13:359-372.
19. Patte C, Auperin A, Gerrard M, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109:2773-2780.
20. Meinhardt A, Burkhardt B, Zimmermann M, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol. 2010;28:3115-3121.
21. Miles R, Arnold S, Cairo M. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Hematol. 2012;156:730-743.
22. Cairo M, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non- Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736-2743.